Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
01 February 2001Website:
http://www.exactsciences.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 39 min agoDividend
Analysts recommendations
Institutional Ownership
EXAS Latest News
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.
Exact Sciences presents new positive evidence backing the development of an MCED test.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening m.
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG takes place October 25-30, 2024, in Philadelphia, Pennsylvania. Exact Sciences will also present new data on improving a.
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
What type of business is Exact Sciences?
Exact Sciences Corporation is one of the leading companies in the development of tests for the diagnosis of oncological diseases. It is the developer of several of the most effective test brands in the field of cancer screening and diagnosis - including Cologuard (diagnosis of colorectal cancer) and Oncotype DX (diagnosis of breast, prostate, and colon cancer). Currently, they are working on creating additional tests for other types of cancer. The company was founded in 1995. The headquarters are located in Madison, Wisconsin. Exact has agreements for cooperation and licensing with the Mayo Clinic Foundation for Medical Education and Research, licensing agreements with Hologic, Biocartis, Epic Sciences, and others.
What sector is Exact Sciences in?
Exact Sciences is in the Healthcare sector
What industry is Exact Sciences in?
Exact Sciences is in the Diagnostics & Research industry
What country is Exact Sciences from?
Exact Sciences is headquartered in United States
When did Exact Sciences go public?
Exact Sciences initial public offering (IPO) was on 01 February 2001
What is Exact Sciences website?
https://www.exactsciences.com
Is Exact Sciences in the S&P 500?
No, Exact Sciences is not included in the S&P 500 index
Is Exact Sciences in the NASDAQ 100?
No, Exact Sciences is not included in the NASDAQ 100 index
Is Exact Sciences in the Dow Jones?
No, Exact Sciences is not included in the Dow Jones index
When was Exact Sciences the previous earnings report?
No data
When does Exact Sciences earnings report?
The next expected earnings date for Exact Sciences is 21 February 2025